Non-Catalytic Inhibitors of the p38/MK2 Interface: Repurposing Approved Drugs to Target Neuroinflammation in Alzheimer’s Disease

Neuroinflammation is a key driver of Alzheimer’s disease and an emerging therapeutic target. The p38/MK2 pathway regulates microglial cytokine production, yet previous attempts have not yielded modulators with clinically suitable properties. Here, we apply an integrative structure-guided and screeni...

Full description

Saved in:

Bibliographic Details
Main Author:	Maylynn Hu (22795608) (author)
Other Authors:	Andrew Li (411246) (author), Payton Fleming (22795611) (author), Julia Gralla (22795614) (author), Kristos Negrón Terón (22795617) (author), Ying Zhou (25031) (author), Eric J. Miller (2570473) (author), Tyler S. Beyett (11586208) (author), Zhexing Wen (3949892) (author), Yuhong Du (1328415) (author), Haian Fu (545475) (author), Andrey A. Ivanov (15155449) (author)
Published:	2025
Subjects:	Biophysics Biochemistry Medicine Molecular Biology Pharmacology Biotechnology Immunology Cancer Chemical Sciences not elsewhere classified yet previous attempts suppresses cytokine release clinically suitable properties repurposing approved drugs putative ppi disruptor identified additional inhibitors emerging therapeutic target blocks mk2 association target neuroinflammation ppi ). drug repurposing catalytic inhibitors mk2 interface mk2 complex yielded modulators virtual screening translational potential throughput assay selectively targeting screening strategy results establish nilotinib binds molecule disruptors modulate neuroinflammation key driver integrative structure including α identify small fret ultrahigh competitive approach based tr alzheimer ’ abl inhibitor
Tags:	Add Tag No Tags, Be the first to tag this record!

Non-Catalytic Inhibitors of the p38/MK2 Interface: Repurposing Approved Drugs to Target Neuroinflammation in Alzheimer’s Disease

Similar Items